Peer-reviewed case report documents 90% volume reduction together with extensive necrosis — achieved without surgery or full-dose chemotherapy after gemcitabine failed
SAN DIEGO, Sept. 7, 2026 /PRNewswire-PRWeb/ -- A peer-reviewed case report from ICCA CancerCare, accepted for publication, describes a marked radiographic response in a 56-year-old man with bulky, locally advanced pancreatic adenocarcinoma. The response was achieved without surgery or full-dose systemic chemotherapy. During treatment, the tumor liquefied and drained through the patient's existing biliary catheter.
The patient's disease had progressed over 17 months following three cycles of gemcitabine at a U.S. academic medical center. At intake on January 26, 2026, the tumor measured 101.3 × 93.7 mm. By May 13, 2026, it measured 87 × 72.9 mm — a 33% reduction in cross-sectional area and a 90% reduction in volume — with extensive internal necrosis. A follow-up PET/CT several months after injection showed only faint residual activity in the pancreatic head with no evidence of metastasis.
Treatment was delivered entirely on an outpatient basis at COFEPRIS-licensed facilities in Tijuana, Baja California, and comprised fractionated radiotherapy with radiosensitizing-dose capecitabine; image-guided intratumoral injection of an EpCAM/CD3 bispecific T-cell-engaging antibody; infusions of allogeneic natural killer cells and autologous lymphocytes; cord blood–derived mesenchymal stromal cells; and sequential pembrolizumab. To the authors' knowledge, this is the first published report of intratumoral EpCAM/CD3 T-cell engagement producing clinically evident tumor lysis in pancreatic cancer.
"A tumor that had progressed through first-line chemotherapy liquefied and drained. That pattern of response is not typical of radiation alone, and it suggests intratumoral immune engagement may open options where standard therapy has failed," said Hebert Schramm, MD, CMO of ICCA CancerCare and corresponding author.
This report describes a single patient. It does not establish safety or efficacy, and individual results vary. The treatments described are administered in Mexico under COFEPRIS authorization and are not approved by the U.S. FDA.
Media Contact
Gregory DiRienzo, ICCA CancerCare, 1 9499390050, [email protected], www.iccacancercare.com
SOURCE ICCA CancerCare
Share this article